SCHEMBL19098914

SCHEMBL19098914

CCCC(CCC)OCc1c(C)cccc1Cl

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.35
▸ KMT2A Q03164 2/20 0.33
▸ POLB P06746 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ ESR1 P03372 2/20 0.32
▸ PKM P14618 1/20 0.32
▸ LMNA P02545 3/20 0.32
▸ CYP1A2 P05177 2/20 0.32
▸ CYP3A4 P08684 2/20 0.32
▸ CYP2D6 P10635 2/20 0.32
▸ CYP2C9 P11712 2/20 0.32
▸ TSHR P16473 2/20 0.32
▸ TAAR1 Q96RJ0 1/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ USP2 O75604 1/20 0.32
▸ ALOX15 P16050 1/20 0.32
▸ CYP2C19 P33261 1/20 0.32
▸ HIF1A Q16665 1/20 0.32
▸ TDP1 Q9NUW8 1/20 0.32
▸ NR1I2 O75469 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19098853 0.83 SMN1; SMN2 (0.38) KDM4EKMT2APOLBSMN1; SMN2ESR1
SCHEMBL19098882 0.83 TAAR1 (0.45) KMT2ASMN1; SMN2LMNATAAR1MEN1
SCHEMBL18371908 0.80 SMN1; SMN2 (0.36) KDM4EKMT2APOLBSMN1; SMN2ESR1
SCHEMBL19099493 0.79 P2RX7 (0.35) KMT2ASMN1; SMN2CYP1A2CYP2C9MEN1
SCHEMBL20091071 0.78 KMT2A (0.47) KMT2ASMN1; SMN2LMNATAAR1MEN1
SCHEMBL19098822 0.77 KMT2A (0.43) KMT2ASMN1; SMN2LMNATAAR1MEN1
SCHEMBL19055368 0.75 SMN1; SMN2 (0.39) KDM4EKMT2APOLBSMN1; SMN2ESR1
SCHEMBL19055623 0.74 KDM4E (0.47) KDM4EKMT2APOLBSMN1; SMN2PKM
SCHEMBL25483117 0.73 PKM (0.36) KDM4EKMT2APOLBSMN1; SMN2PKM
SCHEMBL12016024 0.73 SMN1; SMN2 (0.39) KDM4EKMT2APOLBSMN1; SMN2PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10442798-B2 Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease LYCERA CORPORATION (US) 2019-10-15 — — US disclosed
US-10189777-B2 Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease LYCERA CORPORATION (US) 2019-01-29 — — US disclosed
US-20170190659-A1 BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE WILMINGTON TRUST, NATIONAL ASSOCIATION 2017-07-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10189777-B2 Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease RORC, RORB, RORA KDM4E 2086/4885KMT2A 2706/4885POLB 3653/4885
US-10442798-B2 Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease RORA, RORC, RORB KDM4E 2966/4885KMT2A 1372/4885POLB 4519/4885
US-20170190659-A1 BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE RORB, RORA, RORC KDM4E 2119/4885KMT2A 2458/4885POLB 2985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback